Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 18Recruiting 3Active not recruiting 3Unknown 2Terminated 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2

Interventions

Imatinib Mesylate 17Dasatinib 8nilotinib 7Cytarabine 5Hydroxyurea 4ponatinib 3Peripheral Blood Stem Cell Transplantation 3Interferon-alpha 3bosutinib 2Surveys and Questionnaires 2Stem Cell Transplantation 2Radiotherapy 2Polymerase Chain Reaction 2Pioglitazone 2Idarubicin 2Cytogenetic Analysis 2Busulfan 2Antilymphocyte Serum 2thymoglobulin 1peginterferon alfa-2a 1flumatinib 1fludarabine phosphate 1Tyrosine Kinase Inhibitors 1Therapeutics 1Registries 1Psychiatric Rehabilitation 1Patient Reported Outcome Measures 1PF-114 1Mycophenolic Acid 1Mitoxantrone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × bosutinib × Clear all
NCT04578847 2020-10-08

READIT

National Research Center for Hematology, Russia

Phase 2 Unknown
100 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03205267 2017-07-02

BODO

University of Bonn

Phase 2 Unknown
127 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡